粪菌移植与复发性尿路感染缓解相关
该回顾性研究基于接受粪菌移植治疗复发性艰难梭菌结肠炎的前瞻性数据库,纳入移植前2年内有复发性尿路感染的11例患者,比较移植前后2年内的复发性尿路感染状态和尿路感染频率。
要点
- 粪菌移植后复发性尿路感染全部缓解,无患者再发。
- 移植后2年平均尿路感染次数从3.7次降至0.27次。
- 中位尿路感染复发时间为19.6个月(95%CI 15.2-23.9)。
核心结论
- 粪菌移植与复发性尿路感染缓解及尿路感染频率降低相关。
- 调节肠道菌群可能降低复发性尿路感染风险,支持开展临床试验进一步评估安全性和有效性。
研究设计与样本
- 回顾性分析前瞻性收集的因复发性艰难梭菌结肠炎接受粪菌移植患者的数据库。
- 纳入粪菌移植前2年内有复发性尿路感染的11例患者。
- 比较粪菌移植前2年与移植后2年随访期间的复发性尿路感染状态和尿路感染频率,采用双尾Wilcoxon配对符号秩检验。
主要发现
- Kaplan-Meier估计的中位尿路感染复发时间为19.6个月(95%CI 15.2-23.9)。
- 粪菌移植前后抗生素敏感性谱无显著差异。
关键数值与推荐
- 复发性尿路感染定义为6个月内2次或1年内3次尿路感染发作。
临床怎么用
- 粪菌移植可能作为复发性尿路感染的一种潜在干预策略,尤其适用于合并复发性艰难梭菌结肠炎的患者。
- 目前证据尚不足以常规推荐粪菌移植用于复发性尿路感染,需等待临床试验进一步验证安全性和有效性。
局限性
- 回顾性研究设计,样本量小(11例)。
- 研究对象为因复发性艰难梭菌结肠炎接受粪菌移植的患者,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the association of fecal microbiota transplant (FMT) therapy, an effective treatment for recurrent Clostridoides difficile colitis, with resolution of recurrent UTI (rUTI). METHODS: A prospectively accrued database of patients who underwent FMT for recurrent C difficile colitis was retrospectively reviewed for individuals with rUTI in the 2 years prior to FMT. rUTI status (defined as two UTI episodes in 6 months or three UTI episodes in 1 year) and UTI frequency in the 2 years prior to the FMT were compared to those in the 2 year follow up period after FMT using the two-tailed Wilcoxin matched pairs signed rank test. A P value <.05 was considered statistically significant. RESULTS: Of 11 patients who had rUTI in the 2 years preceding FMT, no patient had rUTI over the follow up period following FMT (P = .001). The average number of UTIs in the two years prior to FMT was 3.7 (range 2-6), and the average number of UTIs in the follow up period was 0.27 (range 0-1) (P = .001). The Kaplan-Meier estimate, the median time to UTI recurrence, was 19.6 months (95% CI: 15.2-23.9). There was no marked difference in antibiotic susceptibility profiles before and after FMT. CONCLUSION: FMT was associated with resolution of rUTI and reduction in UTI frequency in this cohort. The results of this study support the hypothesis that modulation of the gut microbiome may reduce rUTI risk and support a clinical trial to further assess the safety and efficacy of FMT for rUTI.
引用
- Jeong SH, Vasavada SP, Lashner B, et al. Fecal Microbiota Transplant Is Associated With Resolution of Recurrent Urinary Tract Infection. Urology. 2025. PMID: 40447159. doi:10.1016/j.urology.2025.05.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。